Colorectal Cancer

Priority review was granted by the FDA to a supplemental new drug application for adagrasib plus cetuximab for the treatment of advanced KRAS G12C–mutated colorectal cancer.

Favorable ECOG performance status and less advanced disease may predict which patients with metastatic colorectal cancer might have long-term remission when treated with regorafenib.

Consuming navy beans daily as a dietary intervention may contribute to the health of the body's microbiome.

First-line treatment with nivolumab plus ipilimumab for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer can be considered a standard-of-care option based on results from the phase 3 CheckMate-8HW trial.

Fruquintinib showed potential in providing an improved quality of life and survival benefit in patients with previously treated metastatic colorectal cancer.

Detecting minimal residual disease with ctDNA in patients with stage II/III colorectal cancer may strongly predict disease recurrence and the potential benefit from adjuvant chemotherapy.

The median overall survival was 77.5 months with frontline pembrolizumab vs 36.7 months with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.

Holly Chitwood, DNP, APRN, FNP-C, AGACNP-BC, shares her real-world experience with circulating-tumor-DNA monitoring in the colorectal cancer setting.

Tammy Triglianos, DNP, ANP-BC, AOCNP, discusses optimal adjuvant treatment approaches for patients with stage III colon cancer.

The FDA has approved fruquintinib to treat adults with metastatic colorectal cancer.

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

A structured exercise program may aid in preventing colorectal cancer in patients with Lynch syndrome.

Sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer.

Cancer screening tests may not extend life expectancy; however, they still are valuable for public health.

It is essential to continue to develop and incorporate educational strategies to increase screening for colorectal cancer in our communities.

Circulating tumor DNA analysis is playing an increasingly important role in colorectal cancer treatment decision-making.

A triplet regimen of trifluridine, tipiracil, and bevacizumab has been approved as a treatment for patients with metastatic colorectal cancer.

Tucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.

Adverse experiences, such as smoking and experiencing physical abuse, do not necessarily decrease the frequency of colorectal cancer screenings.

Both the gastric and breast cancer HER2 scoring algorithms may be useful in determining which patients with metastatic colorectal cancer may derive benefit with tucatinib/ trastuzumab.

The FDA has granted accelerated approval to tucatinib and trastuzumab for RAS wild-type, HER2-positive metastatic colorectal cancer. The prescribing information includes warnings for diarrhea and hepatotoxicity.

The USPSTF recommends that colorectal cancer screening start at age 45.

Healthcare providers of all disciplines should work together to educate individuals about the symptoms of colorectal cancer.

Preliminary findings from the SLI phase of the BEACON CRC trial show tri-drug combo has durable response in patients with BRAF V600E-mutant metastatic CRC.